Cleveland State University

EngagedScholarship@CSU
Chemistry Faculty Publications

Chemistry Department

1-22-2016

Identification of Critical Paraoxonase 1 Residues Involved in High
Density Lipoprotein Interaction
Xiaodong Gu
Cleveland Clinic

Ying Huang
Cleveland State University

Bruce S. Levison
Cleveland Clinic

Gary Gerstenecker
Cleveland State University

Anthony J. DiDonato
Cleveland Clinic

See next page for additional authors
Follow this and additional works at: https://engagedscholarship.csuohio.edu/scichem_facpub
Part of the Chemistry Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Gu, Xiaodong; Huang, Ying; Levison, Bruce S.; Gerstenecker, Gary; DiDonato, Anthony J.; Hazen, Leah B.;
Lee, Joonsue; Gogonea, Valentin; DiDonato, Joseph A.; and Hazen, Stanley L., "Identification of Critical
Paraoxonase 1 Residues Involved in High Density Lipoprotein Interaction" (2016). Chemistry Faculty
Publications. 315.
https://engagedscholarship.csuohio.edu/scichem_facpub/315

This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU.
It has been accepted for inclusion in Chemistry Faculty Publications by an authorized administrator of
EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.

Authors
Xiaodong Gu, Ying Huang, Bruce S. Levison, Gary Gerstenecker, Anthony J. DiDonato, Leah B. Hazen,
Joonsue Lee, Valentin Gogonea, Joseph A. DiDonato, and Stanley L. Hazen

This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scichem_facpub/315

crossmark
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 291, NO. 4, pp. 1890 –1904, January 22, 2016
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

Identification of Critical Paraoxonase 1 Residues Involved in
High Density Lipoprotein Interaction*
Received for publication, July 11, 2015, and in revised form, November 12, 2015 Published, JBC Papers in Press, November 13, 2015, DOI 10.1074/jbc.M115.678334

Xiaodong Gu‡1, Ying Huang‡, Bruce S. Levison‡, Gary Gerstenecker§, Anthony J. DiDonato‡, Leah B. Hazen‡,
Joonsue Lee‡, Valentin Gogonea‡§, Joseph A. DiDonato‡, and Stanley L. Hazen‡¶2
From the ‡Department of Cellular and Molecular Medicine, Center for Cardiovascular Diagnostics and Prevention, and
¶
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195 and the §Department of Chemistry, Cleveland
State University, Cleveland, Ohio 44115

* This work was supported in part by National Institutes of Health Grants P01
HL076491 and P01 HL103453. S. L. H. is named as co-inventor on pending
and issued patents held by the Cleveland Clinic relating to cardiovascular
diagnostics and therapeutics. S. L. H. reports having been paid as a consultant for the following companies: Esperion and Procter & Gamble. S. L. H.
reports receiving research funds from Abbott, Astra Zeneca, Liposcience
Inc., Procter & Gamble, Pfizer Inc., Roche Diagnostics, and Takeda. S. L. H.
reports having the right to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from the following companies: Cleveland HeartLab, Siemens, Esperion, Frantz Biomarkers, LLC. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Institutes
of Health.
1
Supported in part by a Fellowship Award from the American Heart
Association.
2
Supported in part by a gift from the Leonard Krieger endowment. To whom
correspondence should be addressed: Dept. of Cellular and Molecular
Medicine, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave.,
NC-10, Cleveland, OH 44195. Tel.: 216-4459763; Fax: 216-444-9404; E-mail:
hazens@ccf.org.

1890 JOURNAL OF BIOLOGICAL CHEMISTRY

the PON1-HDL interaction. More generally, the new photoactivatable and affinity-tagged lipid probe developed herein should
prove to be a valuable tool for identifying contact sites supporting protein interactions with lipid interfaces such as found on
cell membranes or lipoproteins.

Ever since the Framingham heart study revealed the inverse
relationship between high density lipoprotein (HDL) cholesterol levels and the risk of coronary artery disease, the structure
and biological functions of HDL have been under intense scrutiny (1– 6). HDL and its major structural protein component,
apolipoprotein A-I (apoA-I), play a pivotal role in mediating
reverse cholesterol transport, which describes the process of
cholesterol removal from peripheral tissues for ultimate elimination from the body by excretion (2, 7–9). Although facilitation of reverse cholesterol transport through cholesterol acceptor activity is considered a major function of HDL particles,
ample evidence shows additional functions exist, such as antioxidant, anti-inflammatory, and anti-tumorigenic activities,
and the shuttling of microRNAs or lipid-signaling molecules
(10 –16). HDL is a highly heterogeneous array of distinct particles, with differing associated proteome and peptidome (17–
22). In addition to exchangeable apolipoproteins, early proteomics studies revealed the HDL-associated proteome
includes known participants critical to hemostasis and thrombosis, innate and adaptive immune function, growth factors
and various receptors, and hormone-associated proteins (17,
20). In the years that have followed since the original HDL
proteomics studies, subsequent reports have confirmed and
expanded upon these earlier findings, revealing a remarkably
complex HDL-associated proteome that can differ as a function
of disease status or susceptibility (23–25). Thus, alterations in
HDL function appear to be, at least in part, dictated by changes
in the complement of HDL-associated proteins present, with
distinct HDL particle subpopulations composed of unique and
dynamically changing clusters of specific HDL-associated proteins (24 –29).
One subpopulation of HDL particles of interest are those
enriched in paraoxonase 1 (PON1). Early genetic and dietary
studies in mouse models revealed PON1 to be an atheroprotective protein (30). Localized to the HDL particle, PON1 has been
shown to contribute to HDL-associated anti-oxidative, antiinflammatory, and cholesterol efflux functions (10, 12, 24, 31).
PON1 has also been shown to stimulate HDL-dependent nitric
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Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)associated protein with atherosclerosis-protective and systemic
anti-oxidant functions. We recently showed that PON1,
myeloperoxidase, and HDL bind to one another in vivo forming
a functional ternary complex (Huang, Y., Wu, Z., Riwanto, M.,
Gao, S., Levison, B. S., Gu, X., Fu, X., Wagner, M. A., Besler, C.,
Gerstenecker, G., Zhang, R., Li, X. M., Didonato, A. J., Gogonea,
V., Tang, W. H., et al. (2013) J. Clin. Invest. 123, 3815–3828).
However, specific residues on PON1 involved in the HDL-PON1
interaction remain unclear. Unambiguous identification of protein residues involved in docking interactions to lipid surfaces
poses considerable methodological challenges. Here we describe a new strategy that uses a novel synthetic photoactivatable and click chemistry-taggable phospholipid probe, which,
when incorporated into HDL, was used to identify amino acid
residues on PON1 that directly interact with the lipoprotein
phospholipid surface. Several specific PON1 residues (Leu-9,
Tyr-185, and Tyr-293) were identified through covalent crosslinks with the lipid probes using affinity isolation coupled to
liquid chromatography with on-line tandem mass spectrometry.
Based upon the crystal structure for PON1, the identified residues are all localized in relatively close proximity on the surface
of PON1, defining a domain that binds to the HDL lipid surface.
Site-specific mutagenesis of the identified PON1 residues
(Leu-9, Tyr-185, and Tyr-293), coupled with functional studies,
reveals their importance in PON1 binding to HDL and both
PON1 catalytic activity and stability. Specifically, the residues
identified on PON1 provide important structural insights into
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The abbreviations used are: pac-PC, photoactivatable and clickable-phosphatidylcholine; rHDL, reconstituted nascent HDL; Ni-NTA, nickel-nitrilotriacetic acid; DMPA, 1,2-dimyristoyl-sn-glycero-3-phosphate; SPR, surface
plasmon resonance.
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Experimental Procedures
General Methods—All solvents used for synthesis were distilled under a nitrogen atmosphere prior to use, and all materials were obtained from Sigma unless specified otherwise. Chromatography was performed with ACS-grade solvents. Progress
of synthetic reactions was monitored by thin layer chromatography, and Rf values are quoted for silica gel-coated plates of
0.25-mm layer thickness. The plates were visualized with
iodine. Flash column chromatography (50) was performed on
230 – 400-mesh silica gel supplied by EMD Millipore. Protein
content was measured using the Markwell-modified Lowry
method (51) with bovine serum albumin as a standard. PON1
activity measurements (paraoxonase and arylesterase activities) were performed as described previously (39). Proton magnetic resonance (1H NMR) spectra were recorded on a Varian
Inova AS400 spectrometer operating at 600 MHz. Proton
chemical shifts are reported as parts per million (ppm) on the ␦
scale relative to CDCl3 (␦ 7.24). 1H NMR spectral data are tabulated in terms of multiplicity of proton absorption (s, singlet;
d, doublet; t, triplet; m, multiplet; br, broad), coupling constants
(Hz), and number of protons. The UV light source (365 nm) was
supplied by a Spectroline Model ENF-280C lamp suspended
just over the top of the sample tubes.
Chemical Syntheses of 1,2-Dimyristoyl-sn-glycero-3-phospho2-(3-methyl-3H-diazirin-3-yl)ethanol—1,2-Dimyristoyl-sn-glycero-3-phosphate (DMPA, 200 mg, 0.33 mmol, CordenPharma, Boulder, CO), 2-(3-methyl-3H-diazirin-3-yl)ethanol
(70 l, 0.7 mmol) (52, 53), and 2,4,6-triisopropylbenzenesulfonyl chloride (300 mg, 0.96 mmol) were dissolved in 10 ml of
anhydrous pyridine, and the reaction mixture was stirred overnight at room temperature. The reaction was quenched by adding 0.5 ml of water. Pyridine was removed by rotary evaporation. The residue was suspended in 70 ml of cold ether at 4 °C
overnight. After filtration, the ether was removed by rotary
evaporation. The crude product was purified by silica gel chromatography eluting with 10% methanol in chloroform to obtain
the pure product (139.4 mg, yield 63%, Rf⫽ 0.37 (CHCl3/
CH3OH/H2O ⫽ 15:5:0.5)). 1H NMR (600 MHz, CDCl3) ␦ 5.28
(br, 1H), 4.42 (br, 1H), 4.18 (br, 1H), 3.98 (br, 2H), 3.77 (br, 2H),
2.40 –2.20 (4H), 1.70 –1.50 (6H), 1.30 –1.10 (40H), 1.03 (s, 3H),
0.85 (t, 6H). Negative ESI-MS/MS analysis yielded the following
diagnostic parent and fragment ions: m/z 673.8 [M ⫺ H]⫺; m/z
645.6, 435.5, 227.6.
Chemical Syntheses of 1-Myristoyl-sn-glycero-3-phospho-2(3-methyl-3H-diazirin-3-yl)ethanol—1,2-Dimyristoyl-sn-glycero-3-phosphatidyl-2-(3-methyl-3H-diazirin-3-yl)ethanol (100
mg, 0.15 mmol) in a 50-ml centrifuge tube as dry film was suspended in 20 ml of PBS buffer (10 mM, pH 8.0, and containing
CaCl2 5 mM) and was vortexed for 5 min. 500 l of phospholipase A2 (100 units, Sigma P6534-10MG) was added. The
resulting mixture was gently vortexed for another 2 min and
incubated at 37 °C in a shaker overnight. Lipids were extracted
by the Bligh and Dyer method (54), and the aqueous phase was
extracted with chloroform (10 ml 2 times). Organic solvents
were combined and evaporated. The crude product was purified on a silica gel column eluting with 15% methanol in chloroform to obtain the pure product (45 mg, yield 65%, Rf ⫽ 0.2,
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oxide (NO) production by endothelial nitric-oxide synthase
(10, 32–34). PON1 possesses both esterase and lactonase catalytic activities in vitro but has unclear substrate(s) in vivo (35). A
role for PON1 protection from atherosclerosis in vivo has been
supported by studies showing PON1 knock-out mice have
accelerated atherosclerosis (36), and human PON1 transgenic
mice demonstrate both protection from atherosclerosis and
reduced indices of systemic oxidative stress (31, 37). In human
studies, a striking correlation between multiple systemic measures of oxidant stress and serum PON1 activity measures has
also been established (12, 31). Moreover, reduced systemic
PON1 activity has been shown to predict increased prospective
risks for major adverse cardiac events in multiple distinct clinical cohorts (12, 38 – 41). Thus, there is considerable in vitro
and in vivo evidence to support PON1 as an important mediator
of many anti-inflammatory, anti-oxidant, and atheroprotective
activities of HDL.
Knowledge at the structural level of how HDL-associated
proteins interact with HDL particles is in its infancy. In prior
studies, we showed that HDL forms a functional ternary complex with PON1 and myeloperoxidase (31), an oxidant-generating enzyme linked to development of atherosclerosis (42–
48). Each member of the ternary complex was shown to impact
the function of the other in vivo (31). Residues involved in the
protein-protein interaction between PON1 and apoA-I of
HDL, or between myeloperoxidase and apoA-I of HDL, have
thus far been delineated using hydrogen deuterium exchange
mass spectrometry-based methodology as a discovery platform,
coupled with site-specific mutagenesis and functional studies
to determine the significance of the residues involved (31, 49).
Despite the many recent advances made, a full understanding of
how PON1 interacts with HDL remains unclear. For example,
PON1 binding to HDL lipid and membrane surfaces is known
to be essential for its stability and catalytic activity (31); however, the interaction sites between PON1 and the lipid interface
of HDL remain unknown. Indeed, tools for defining contact
residues between proteins and phospholipid surfaces such as on
a membrane bilayer, or a lipoprotein particle, are not readily
available.
Herein, we describe development, characterization, and
application of a novel tool to interrogate contact residues that
support tight binding interactions with phospholipid surfaces,
a synthetic photoactivatable and “clickable” phosphatidylcholine analogue (pac-PC).3 Using PON1-HDL interactions as a
test case, we illustrate the facile use of this new technology,
defining several key residues on PON1 essential for PON1
docking to HDL, PON1 catalytic activity, and stability. The use
of pac-PC incorporated into recombinant HDL particles or
membrane bilayers may thus serve as a universal strategy to
facilitate identification of residues critical for protein docking
with the lipid surface of lipoproteins or cell membranes.
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incubated at 37 °C for 1 h. This mixture was then transferred
into small glass vials on ice and directly exposed to a 365-nm
UV light for 1 min. Proteins were then precipitated by adding 18
ml of methanol/chloroform/ether, 1:1:2.5 (v/v/v). The precipitated proteins (mixture of apoA-I and PON1) were dissolved in
1 ml of PBS buffer (50 mM, pH 7.0) with 1% SDS and diluted by
addition of 4 ml of PBS buffer (to reduce SDS concentration to
0.2%). Nickel-nitrilotriacetic acid resin (Ni-NTA, 500 l, prewashed and equilibrated in PBS buffer, 50 mM, pH 7.0) was
added to enrich His-tagged PON1 and to remove human
apoA-I. rPON1 was eluted with PBS buffer (50 mM, pH 7.0)
containing 0.2% SDS and 200 mM imidazole. rPON1 was again
precipitated by using methanol/chloroform/ether, 1:1:2.5
(v/v/v).
Adding Biotin Tag to pac-PC Cross-linked Proteins through
Click Chemistry—Precipitated protein (apoA-I or rPON1) that
had been cross-linked with the pac-PC was dissolved in 1 ml of
PBS buffer (50 mM, pH 7.0, and with 1% SDS). Biotin-azide (61)
(4 l, 30 mM in dimethylformamide) was added, and the mixture was vortexed for 1 min. Then, freshly made tris(2-carboxyethyl)phosphine (20 l, 50 mM in water) was added, followed by
the addition of tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]
amine (20 l, 5 mM in DMSO/t-butanol ⫽ 1:4), and the mixture
was vortexed for another 1 min. The reaction was initiated with
CuSO4 (50 l, 20 mM stock solution in water) and the mixture
was vortexed for 1 min. The reaction mixture was left at room
temperature for 1 h (and vortexed after 30 min). Reaction product was transferred into Slide-a-Lyzer dialysis cassettes
(Thermo Scientific) and dialyzed against 4 liters of PBS buffer at
4 °C (buffer changed three times in 24 h).
Affinity Purification of pac-PC-modified Peptides—The affinity purification of pac-PC cross-linked proteins and subsequent
on-bead trypsin/chymotrypsin digestion steps were performed
using the general tandem orthogonal proteolysis strategy
described by Weerapana et al. (62). Briefly, photoactivatable
lipid probe (pac-PC) cross-linked and biotin-tagged proteins
(apoA-I or rPON1) were incubated with neutravidin beads (200
l, 1:1 slurry, pre-washed and equilibrated in PBS buffer) for 3 h
at room temperature. Supernatant was removed by centrifugation at 1400 ⫻ g for 3 min. Neutravidin beads were washed by 5
ml of PBS (with 0.2% SDS) three times and followed by 5 ml of
water. Beads were transferred into a low retention Eppendorf
tube and incubated with a premixed solution (200 l of 1 M
urea/PBS, 2 l of 1 M calcium chloride in water, and 4 l of 0.5
g/l trypsin or chymotrypsin) at 37 °C overnight with rotations. Neutravidin beads were washed with PBS buffer (3 ⫻ 500
l) and water (3 ⫻ 500 l). To release the biotinylated peptides
from neutravidin beads, the beads were treated with 50:50 (v/v)
water/acetonitrile containing 0.1% trifluoroacetic acid (200 l,
65 °C, 5 min) as described previously (63). Beads were removed
via filtration through a spin column and washed with 50:50
(v/v) water/acetonitrile (2 ⫻ 100 l) for a total elution volume
of 400 l. The solvent was evaporated under N2 flow to a final
volume of ⬃25 l and was diluted by another 25 l of 0.1%
formic acid/water. For the base treatment, sodium hydroxide (1
M in water, 5 l) was added, and the resulting mixture was
incubated at room temperature for 3 h. Then acetic acid (2 M in
water, 3 l) was added to neutralize the sample. The samples
VOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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25% methanol in chloroform). Negative ESI-MS/MS analysis
yielded the following parent and diagnostic fragment ions: m/z
463.7 [M ⫺ H]⫺; m/z 435.6, 365.5, 227.7.
Chemical Syntheses of 1-Myristoyl-2-(10-undecynoyl)-snglycero-3-phospho-2-(3-methyl-3H-diazirin-3-yl)ethanol (pac-PC)—
1-Myristoyl-sn-glycero-3-phosphatidyl-2-(3-methyl-3H-diazirin-3-yl)ethanol (20 mg, 0.043 mmol), 10-undecynoic acid (40
mg, 0.22 mmol), N,N⬘-dicyclohexylcarbodiimide (26 mg, 0.126
mmol), and 4-dimethylaminopyridine (5 mg, 0.043 mmol) were
dissolved in 2 ml of anhydrous chloroform and stirred at room
temperature for 48 h. Solvents were removed by rotary evaporation. The crude product was purified on a silica gel column
eluted with 10% methanol in chloroform to deliver the final
product (20.4 mg, yield 75%, Rf ⫽ 0.36 with 20% methanol in
chloroform). 1H NMR (600 MHz, CDCl3) ␦ 5.28 (br, 1H), 4.35
(br, 2H), 4.14 (br, 2H), 4.02 (br, 1H), 3.82 (br, 1H), 2.40 –2.20
(4H), 2.20 –2.10 (2H), 1.92 (m, 1H), 1.70 –1.55 (6H), 1.50 (m,
2H), 1.30 –1.10 (28H), 1.04 (s, 3H), 0.86 (t, 3H). Negative ESIMS/MS analysis yielded the following diagnostic parent and
fragment ions: m/z 627.7 [M ⫺ H]⫺; m/z 599.5, 435.5, 228.3,
182.1.
Preparation of Reconstituted Nascent HDL Containing
pac-PC—All human biological materials were obtained from
participants that gave written informed consent for protocols
approved by the Cleveland Clinic Institutional Review Board.
Human HDL was isolated from plasma of healthy volunteers by
sequential buoyant density ultracentrifugation using KBr to
adjust density to the range of 1.07–1.21 g/ml, as described previously (55–57). Lipid-free human apoA-I was prepared by
delipidation of isolated human HDL using methanol/ether/
chloroform followed by ion exchange chromatography. The
purity of isolated human apoA-I was verified by SDS-PAGE.
Reconstituted nascent HDL (rHDL) was prepared using the
sodium cholate dialysis method of Matz and Jonas (58) as modified by Barter and co-workers (59). An initial molar ratio of
98:2:10:1 of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine/pac-PC/cholesterol/isolated human apoA-I was used for
reconstituted HDL preparation.
Photoactivatable Cross-linking between pac-PC and Human
apoA-I or PON1—Control studies showed that pac-PC is stable
(at least on the time scale of many minutes to hour) under
normal ambient light conditions. All studies described were
performed under ambient light conditions. Nonetheless, exposure of pac-PC to light was minimized at all times (except for
UV exposure), by keeping the photo-lipid in screw cap glass
reaction vials wrapped in foil.
(i) The cross-linking between pac-PC and human apoA-I/
rHDL with pac-PC (human apoA-I concentration of 70 M) in
0.5 ml of 50 mM PBS buffer at pH 7.0 was transferred into small
glass vials on ice and then directly exposed to 365 nm UV light
for 1 min. Proteins were then precipitated by adding 9 ml of
methanol/chloroform/ether, 1:1:2.5 (v/v/v).
(ii) The cross-linking between pac-PC and PON1/rHDL with
pac-PC (human apoA-I concentration of 70 M) in 0.5 ml of 50
mM PBS buffer at pH 7.0 was incubated with recombinant Histagged PON1 (rPON1, 30 M, in 0.5 ml of 50 mM Tris buffer
with 1 mM CaCl2, pH 7.0) that was expressed and purified from
Escherichia coli, as described previously (60). The mixture was
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pan-K mutants) were prepared as 0.1 mg/ml samples in 10 mM
phosphate buffer, pH 7.0, supplemented with 0.2 mM CaCl2,
and analyzed at ambient temperature in continuous scan mode
with a 1-nm bandwidth (100,000 counts/step).
Surface Plasmon Resonance (SPR)—Full time course kinetic
determinations of kon, koff, and apparent equilibrium dissociation constants Kd for rHDL interaction with rPON1 forms were
determined using SPR using a BIAcore 3000 SPR biosensor
(BIAcore, AB). Briefly, rHDL was directly immobilized on a
CM5 sensor chip. To determine the Kd value between distinct
rPON1 and rHDL, rPON1 ranging from 500 to 2000 nM were
prepared in PON1 activity buffer (50 mM Tris, 50 mM NaCl, 1
mM CaCl2, pH 8.0) and flowed over the surface of the sensor
chip at a rate of 20 l/min. At the end of each cycle, surfaces of
the sensor chips were regenerated by injection of 15 mM HCl at
the same flow rate. Apparent Kd values were obtained by fitting
background-subtracted SPR binding data to the 1:1 binding
with drifting baseline model within the BIAevaluation software
version 4.0.
Stability Studies of rPON1 Mutants—rPON1 was preincubated with rHDLs (2 eq) or 0.1% tergitol (NP-10, Sigma) in
PON1 activity buffer (50 mM Tris, 50 mM NaCl, and 1 mM
CaCl2, pH 8.0) at 37 °C for 30 min. Inactivation was initiated by
adding an equal volume of inactivation buffer (10 mM EDTA
and 20 mM ␤-mercaptoethanol in 50 mM Tris, pH 8.0) and incubating the samples at 37 °C. Aliquots were taken at various time
points, and the arylesterase activity was examined as described
previously (39).

Results
Photoactivatable Lipid Probe Design and Chemical Synthesis—Plasma HDL particles represent an ensemble of lipidated apoA-I core lipoprotein (75% protein mass of HDL) with
numerous distinct interacting HDL-associated proteins.
Remarkably, despite the interest in HDL biology and the role in
cardiovascular disease, an understanding of the structural
regions on virtually all HDL-associated proteins critical for
docking to the lipoprotein lipid surface is poorly defined. This is
because few specific and effective tools exist for direct detection
of protein contact points with lipid surfaces, whether it be a
lipoprotein, a cell membrane, or a microparticle. To address
this unmet need, we designed a photoactivatable and clickable
phospholipid probe, pac-PC (Fig. 1A). Phosphatidylcholine is
the most abundant class of phospholipid in most lipoproteins
and membranes. Our photoaffinity lipid (pac-PC) is an analogue of phosphatidylcholine, which harbors a diazirine ring
that replaced the trimethylamine moiety of the choline polar
headgroup. Upon exposure to ultraviolet (UV, 365 nm) radiation, the diazirine ring readily expels N2 generating a reactive
diradical carbene species. Carbenes rapidly insert into proximate protein backbones or side chains in nanoseconds, and if
not are then scavenged by water at near the diffusion-limited
rate. Thus, our probe design ensures that detection of a covalent adduct between the phospholipid probe and a protein indicates the existence of a tight enough binding interaction to
exclude water (66). In addition, to facilitate subsequent affinity
isolation of adducts, we also introduced a terminal alkyne group
on an sn-2 position aliphatic chain, providing a useful handle
JOURNAL OF BIOLOGICAL CHEMISTRY
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were analyzed by liquid chromatography with on-line electrospray ionization tandem mass spectrometry (LC/MS/MS).
Mass Spectrometry Analysis—All mass spectrometry analyses were performed under the Xcalibur data system using
Proxeon Easy-nLC coupled to a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific) with a nano-LC electrospray ionization source. Samples were first pressure-loaded onto an IntegraFrit sample trap (inner diameter 100 m, length 2.5 cm, New
Objective) and separated by a PicoFrit column (stock number
PF360-75-15-N-5, New Objective) packed in our laboratory
(packing material: C18, 300 Å, 5 m from Cobert Associates).
Mobile phase was as follows: buffer A/water with 0.1% formic
acid; buffer B/acetonitrile with 0.1% formic acid. The HPLC
gradient started with 5% B and increased to 40% B over 60 min,
then increased to 80% B over 5 min, and held at 80% B for
another 10 min. For repeat injections on autosampler, the column was re-equilibrated for the next sample by decreasing to
5% B over 2 min and held at this solvent composition for 20 min.
Flow rate was 0.2 l/min. The applied spray voltage of the
nano-LC electrospray ionization source was 2.0 kV. For MS2
data collection, one full scan by Orbitrap was followed by 10
data-dependent scans of the most intense ions by ion trap.
Dynamic exclusion was also applied so that any ions that had
been repeatedly scanned three times in 60 s would be excluded
for scan for 3 min.
Mass spectra were subject to SEQUEST (64) (Thermo Scientific) and searched against a PON1.fasta database. A static modification ⫹926.532, corresponding to the lipid probe, was
applied to each amino acid residue. SEQUEST output files were
filtered by XCorr (cross-correlation value, minimal XCorr ⫽
1.8(⫹1), 2.5(⫹2), 3.5(⫹3) as described in the DTASelect (65)).
For base-treated samples, a static modification of ⫹226.061
corresponding to a glycerol phosphate group was used. Other
possible modifications were also applied during the SEQUEST
search, including oxidation on methionine (⫹16), deamination
of glutamine and asparagine (⫹1), and dehydration of serine
and threonine (⫺18). All targeted peptides spectra were examined by manual inspection.
Site-specific Mutations of Recombinant Paraoxonase 1
(rPON1)—Site-specific mutants of rPON1 used included the
G3C9 PON1 clone (60) on the wild type (WT) backbone
sequence. The pan-E PON1 mutant (L9E, Y185E, and Y29E),
pan-K PON1 mutant (L9K, Y185K, and Y293K), PON1
(Y293K), and PON1 (Y294K) with a His8 tag directly at their C
terminus were prepared from codon-optimized WT rPON1
directly synthesized by GenScript (Piscataway, NJ) and cloned
at NcoI-HindIII restriction sites into the pBAD vector (Invitrogen). Competent TOP10 (Invitrogen) E. coli cells were transfected with the plasmids for the expression of the recombinant
proteins. Wild type and mutant rPON1s were purified by NiNTA affinity chromatography to homogeneity, with purity of
proteins confirmed by SDS-PAGE.
Spectral Studies of rPON1 Mutants—Far-UV circular dichroism spectra were recorded on a Pistar180 spectropolarimeter
(Applied Photophysics, Surrey, UK). Standardization was performed with an aqueous solution of 0.06% ammonium d-(⫹)10-camphor sulfonate at a wavelengths of 260 to 200 nm and
with a path length of 10 mm. rPON1 forms (WT, pan-E, and
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FIGURE 1. Design and chemical synthesis of the lipid probe pac-PC. A,
chemical structure of pac-PC. pac-PC is an analogue of phosphatidylcholine,
with two extra function groups as follows: one diazirine group (in dashed
circle) on sn-3 headgroup and one alkyne group (in dashed square) on sn-2
fatty acid side chain terminal. The carbene di-radical (in dashed circle) is generated after UV irradiation. The terminal alkyne reacts with biotin azide to give
a triazole (in dashed square). B, chemical synthesis of pac-PC began from a
commercially available lipid (DMPA). Briefly, after being coupled with 2-(3methyl-3H-diazirin-3-yl)ethanol, the sn-2 side chain was removed through
phospholipase A2-catalyzed hydrolysis. Further reaction of the lyso-lipid with
10-undecynoic acid in the presence of coupling reagents dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) delivered the final product, pac-PC. Details are under “Experimental Procedures.”

for the later addition of a biotin tag through highly efficient and
selective click chemistry (Fig. 1A) (67, 68).
The synthetic route to the new lipid probe, pac-PC, is shown
in Fig. 1B. The chemical synthesis is described in detail under
“Experimental Procedures” and began from a commercially
available lipid (DMPA). Briefly, after being coupled with 2-(3methyl-3H-diazirin-3-yl)ethanol (69), the sn-2 side chain was
removed through phospholipase A2-catalyzed hydrolysis (70).
Further reaction of the lysolipid with 10-undecynoic acid in
the presence of coupling reagents dicyclohexylcarbodiimide
and 4-dimethylaminopyridine delivered the final product,
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pac-PC (71). The synthesized lipid probe was purified by
HPLC and extensively characterized by nuclear magnetic
resonance (NMR) and mass spectrometry to confirm its
purity and validate its structure, as outlined under “Experimental Procedures.”
Photoactivatable Lipid (pac-PC) Cross-linked with ApoA-I in
HDL—Photoactivatable lipids have been used to isolate and
identify proteins that interact with lipids (72). However, subsequent mass spectrometry analyses to define the exact contact
residues of target proteins remain a daunting challenge, as the
methods to selectively identify precisely the amino acid residues has not yet been developed. Because apoA-I interacts with
phospholipids in nascent HDL particles, we initially examined
the interaction of pac-PC with apoA-I in HDL to develop the
necessary analytical and mass spectrometry methods. The
experimental scheme we used to study lipid-protein interaction
in nascent HDL is outlined in Fig. 2. rHDL was prepared as
outlined under “Experimental Procedures” using a modified
sodium cholate dialysis method containing a low mol % of the
photoactivatable lipid probe, pac-PC, to minimize potential
structural perturbations to the particle. Control studies (equilibrium native PAGE and dual beam light scattering) showed
that the rHDL particles thus generated had similar size compared with rHDL lacking the probe (data not shown). Following
exposure to UV irradiation, the pac-PC adduct was biotinylated
using click chemistry as outlined under “Experimental Procedures.” Tagged apoA-I was then subject to neutravidin affinity
column enrichment followed by on-bead trypsin digestion, as
described under “Experimental Procedures.” Following a wash
step, pac-PC-modified apoA-I peptides were eluted from the
beads and then analyzed by LC/MS/MS (Fig. 2).
Despite initial efforts to deconvolute the raw spectra with
SEQUEST searches, no modified peptides were identified (even
when the XCorr values were lowered to 1.0(1⫹), 2.0(2⫹),
3.0(3⫹)). However, manual inspection of the raw peptide specVOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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FIGURE 2. Experimental scheme using pac-PC to investigate pac-PCapoA-I interaction. rHDL was prepared as described under “Experimental
Procedures” and contained 2 mol % of pac-PC. After UV irradiation, the pacPC/apoA-I cross-linking products were biotinylated using click chemistry. Biotin-tagged pac-PC/apoA-I adducts were enriched by neutravidin collection
and trypsinized, and unbound peptides were washed away. Following the
wash step, pac-PC-modified apoA-I peptides were eluted from the beads. In
later experiments, base hydrolysis of pac-PC-modified peptides was incorporated at this step to remove the bulk of the lipid side chains allowing accurate
software interrogation of modified peptide adducts by analysis using LC/MS/
MS. Details are under “Experimental Procedures.”
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tra identified abundant spectra with specific daughter fragmentations (ions produced during MS/MS ionization), such as m/z
284 and m/z 775 (one example is given in Fig. 3A) (note: our
method involves two wash steps, which removed non-labeled
apoA-I protein and non-labeled apoA-I peptides, and it made
the manual inspection of the raw spectra possible). Identical
daughter fragmentations (m/z 284 and m/z 775) from different
peptide spectra suggested that the daughter ions at m/z 284 and
m/z 775 were derived from the same source, the lipid modification. To test our hypothesis, we performed a control experiment as illustrated in Fig. 4. The synthetic lipid analogue, pacPC, was either incorporated into HDL (i.e. in the presence of
protein), as outlined above, or incubated alone in buffer (PBS)
and then exposed to UV irradiation. Samples were then incubated with biotin azide to enable click chemistry-based biotinylation, followed by on-bead trypsin digestion and LC/MS/MS
analysis (Fig. 4). The pac-PC sample exposed to UV irradiation
alone in buffer (without the presence of apoA1/HDL), during
MS ionization, gave rise to m/z 284 and m/z 775 as major fragJANUARY 22, 2016 • VOLUME 291 • NUMBER 4
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FIGURE 3. pac-PC-labeled peptides have unique fragmentation patterns
derived from pac-PC. A, one representative tandem mass spectrum of pacPC-modified apoA-I peptide (Thr161-Arg171) having the diagnostic fragments
m/z 284 and m/z 775. B, tandem mass spectrum of pac-PC after photoactivation (in PBS buffer) and click chemistry reaction, which has dominant fragments m/z 284 and m/z 775.

ments, confirming that these daughter ions arise from the
pac-PC moiety itself. Thus, the reasons for difficulty using the
automated peptide sequencing was because the lipid-modified
peptides gave dominant fragments from cleavage of the lipid
instead of from the peptide backbone, complicating spectra
interpretation and resulting in failed software searches.
To circumvent this problem, we added a simple base hydrolysis step to the end of the overall scheme depicted in Fig. 4, the
rationale for which is illustrated in the scheme shown in Fig. 5A.
The ester bonds in lipids are more base-sensitive than amide
bonds in peptides; thus, base-catalyzed hydrolysis effectively
removed the bulk of the lipid fatty acid side chains leaving a
characteristic small modification group (glycerol phosphate,
⫹226.061 atomic mass units). For base-treated samples, we
therefore applied a static modification of ⫹226.061 atomic
mass units to each amino acid for peptide analyses, corresponding to a glycerol phosphate group, as described under “Experimental Procedures.” We found that applying this static
⫹226.061 atomic mass unit modification gave structurally
informative and recognizable peptide backbone fragmentations (Fig. 5). Thus, base-treated peptides were easily identified
and recognized with exact modification sites by SEQUEST. As
expected, examination of peptide spectra from pac-PC-containing rHDL showed that numerous residues throughout the
length of apoA1 may be covalently tagged by pac-PC (one
example is given in Fig. 5).
Use of rHDL Incorporating pac-PC to Identify PON1 Residues
Involved in Binding to the HDL Lipid Surface—Having refined
the above sample processing and mass spectrometry analyses
using this new tool, we next applied it to the study of HDLPON1 interaction, a test case to validate the utility of pac-PC in
defining HDL-associated protein contact sites. A step by step
scheme depicting the overall steps is shown in Fig. 6. Reconstituted nascent HDL incorporating low mol % (2%) pac-PC was
prepared and then incubated with His-tagged rPON1 at 37 °C
for 1 h. Cross-linking was performed as described under
“Experimental Procedures” with brief (1 min) exposure to UV
light (365 nm) at 0 °C. Proteins were precipitated, and then
resolubilized rPON1 was enriched using Ni-NTA resin (to
remove human apoA-I). Immobilized PON1-containing phospholipid adducts were biotinylated via click chemistry, and
then lipid-tagged rPON1 was subjected to neutravidin enrichment and on-bead trypsin/chymotrypsin digestion (Fig. 6). Following a wash step to remove non-labeled peptides, the lipidmodified rPON1 peptides were eluted from the beads. After
base treatment, facile identification of the modification sites on
rPON1 was achieved by LC/MS/MS and searching for glycerolphosphate modified peptides, which were detected by a static
modification (⫹226.061) applied to each amino acid residue.
Three rPON1 peptides (Table 1) were reproducibly identified that carried the specific modification (⫹226.061) corresponding to the glycerol phosphate adduct (Ala2-Lys21, Ile291Lys297, and Ala180-Tyr-190). The residue within each peptide
(Leu-9, Tyr-185 and Tyr-293) carrying the glycerol-phosphate
moiety derived from pac-PC is also shown, along with the excellent (within 10 ppm) agreement between the exact mass experimentally measured for each peptide and its theoretical mass
based on elemental composition (Table 1). For illustrative pur-
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poses, the mass spectra of the native peptide Ile291-Lys297 and
the peptide Ile291-Lys297 carrying the modification at residue
Tyr-293 are presented in Fig. 7, A and B, respectively. Note that
a static mass shift of ⫹226 is observed on related b and y ions
labeled with * in Fig. 7B. Also shown (Fig. 8) is the crystal structure for PON1 (73) with superimposed locations of Leu-9, Tyr185, and Tyr-293, which collectively identify the interfacial surface that binds to the HDL particle. Of interest, PON1 Tyr-71, a
residue we previously showed was in close spatial proximity to
cholesterol within PON1 bound to an HDL particle using a
photoaffinity-labeled cholesterol analogue (31), is similarly
localized close to the identified HDL-binding interface (Fig. 8).
Also of interest and discussed below, PON1 Tyr-294, despite
being within ⬃5 Å with Tyr-293 (␣-carbon to ␣-carbon; Fig. 8),
failed to show pac-PC probe adduct formation in PON1-bound
HDL, illustrating the remarkable specificity of residue interaction and covalent modification by the phospholipid photoactivatable group in the PON1-HDL complex.
As noted above, the rPON1 variant used in this study, G3C9,
has two adjacent tyrosine residues (Tyr-293 and Tyr-294) in
peptide Ile291-Lys297, but sequence analyses of affinity-isolated
peptides recovered from PON1-HDL complexes following
photoactivation of the pac-PC probe repeatedly showed only
PON1 Tyr-293 was covalently adducted to the probe. To confirm that the lipid cross-link was at Tyr-293 instead of Tyr-294,
we performed the more sensitive analysis of selected ion monitoring (m/z 586.3, corresponding to the lipid cross-linked peptide Ile291-Lys297) and collected its daughter fragments. We
were able to successfully isolate a peptide that has the same m/z
value but slightly different retention time, shown as the small
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shoulder peak (peak 1) on the chromatogram (Fig. 9A). This less
abundant peptide, Ile291-Lys297, was observed to carry the lipid
modification at Tyr-294 instead of Tyr-293, based on its
MS/MS fragments (Fig. 9B; adduct at Tyr-294 is estimated to
occur at a 10 –20-fold reduced level compared with adduct at
Tyr-293).
PON1 Residues Leu-9, Tyr-185, and Tyr-293 Are Functionally Important for HDL Binding and Preservation of PON1
Activity—To examine the functional significance of PON1 residues discovered as HDL lipid-binding sites (Leu-9, Tyr-185,
and Tyr-293), we generated site-specific rPON1 mutants. All
mutants were compared with the recombinant PON1 variant
G3C9 (wild type-like activity, rPON1 WT). Residues (Leu-9,
Tyr-185, and Tyr-293) were mutated to either glutamic acid
(rPON1 pan-E) or lysine (rPON1 pan-K). The purified rPON1
mutants (pan-E or pan-K mutants) were observed to be homogeneous and have similar molecular weight, as shown by SDSPAGE (Fig. 10A). Moreover, secondary structure analyses, as
shown by circular dichroism (CD) spectra, revealed minimal
differences when compared with WT rPON1 (Fig. 10B). We
examined the catalytic activities of WT rPON1 and these
rPON1 mutants by using paraoxon (paraoxonase activity) or
phenyl acetate (arylesterase activity) as substrates. Purified
rPON1 pan-K mutant demonstrated a specific activity of ⬃50%
paraoxonase activity and ⬃80% arylesterase activity compared
with rPON1 WT, whereas rPON1 pan-E mutant demonstrated
almost complete loss of activity with either substrate (Fig. 11, A
and B).
We interrogated the functional significance of PON1 residues Leu-9, Tyr-185 and Tyr-293 in HDL docking interactions
VOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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FIGURE 4. Major MS/MS fragments of pac-PC-modified peptides come from lipid portion. The control experiment was performed by using pac-PC vesicles
in PBS buffer. For comparison, the steps for use and analysis of pac-PC-coupled peptides following interaction with protein (as in rHDL) are also shown. After
UV irradiation, pac-PC is biotinylated through click chemistry and affinity-isolated, subjected to trypsinolysis, and analyzed by LC/MS/MS. In the example of only
pac-PC exposed to UV irradiation in buffer alone, the final extracted lipid gave m/z 284 and m/z 775 as major MS/MS fragments, typical patterns from
pac-PC-modified peptides. Thus, fragment ions m/z 284 and m/z 775 originate from the lipid portion of lipid-adducted peptides.
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TABLE 1
Identified rPON1 residues that cross-linked with the photoactivatable
lipid probe pac-PC
FIGURE 5. Simple base hydrolysis step effectively removes the bulk of the
lipid side delivering structurally informative and recognizable peptide
backbone fragmentations. Tandem mass spectrum of pac-PC modified
apoA-I peptide (Thr-161–Arg-171) after base hydrolysis. Amino acid and b/y
ions that carry hydrolyzed pac-PC modification group (⫹226.061) are labeled
with *.

by directly quantifying the collective role of the PON1 residues
in binding to the HDL particle surface. For these studies, the
binding of WT rPON1 (G3C9) and both mutant rPON1 forms
(pan-E and pan-K) with rHDL were examined using surface
plasmon resonance spectroscopy. Reconstituted HDL particles
were directly coated on the sensor chips, and then diluted
rPON1 solutions of different concentrations were individually
flowed over the immobilized rHDL. Measured kon, koff, and Kd
values for each PON1 form interaction with rHDL are shown in
Table 2, and for illustrative purposes, typical binding sensorgrams for binding of rPON1 WT or rPON1 pan-K to rHDL are
presented in Fig. 12, A and B, respectively. Of note, the rPON1
pan-K mutant showed 1000-fold less binding capacity to rHDL
compared with rPON1 WT (Kd, 1.4 ⫻ 10⫺6 versus 7.1 ⫻ 10⫺10,
respectively, see Table 2). The rPON1 pan-E mutant showed
even lower HDL binding capacity compared with the rPON1
pan-K mutant (Kd, 5.9 ⫻ 10⫺5 versus 1.4 ⫻ 10⫺6, respectively,
see Table 2). These results show that PON1 Leu-9, Tyr-185, and
Tyr-293 participate in PON1-HDL interactions, and the nature
of the site-specific mutations impact the affinity of the PON1
form to bind to HDL.
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4

Three rPON1 peptides were reproducibly identified that carried the specific modification (⫹226.061) corresponding to the glycerol phosphate adduct. The residue
within each peptide (Leu-9, Tyr-185, and Tyr-293) carrying the glycerol-phosphate
moiety derived from pac-PC is also shown, along with the excellent (within 10
ppm) agreement between the exact mass experimentally measured for each
peptide and its theoretical mass based on elemental composition. Mass spectra
were originally filtered by XCorr (cross-correlation value) and were examined
by manual inspection.
Labeled peptide

Labeled
residue [M ⴙ H]ⴙ ⌬M X-Corr
ppm

2

AKLTALTL*LGLGLALFDGQK21 Leu-9
Tyr-293
IFY*YDPK297
180
Tyr-185
ATNDHY*FADPY190
291

2269.2962
1171.5417
1539.6117

4.70 4.57
4.18 2.29
5.07 2.51

PON1 binding to HDL is known to stabilize PON1 catalytic
activity at 37 °C, with both protein (apoA-I) and lipid phase of
HDL contributing to the overall docking and stabilization of
PON1 on the HDL particle (31, 74, 75). We therefore next analyzed the importance of PON1 Leu-9, Tyr-185, and Tyr-293 in
PON1 stabilization with HDL particles. To speed inactivation,
rPON1 (WT versus pan-K form) was incubated with a calcium
chelator (EDTA) and a reducing agent, ␤-mercaptoethanol, in
the presence or absence of rHDL or detergent (0.1% tergitol
(Nonidet P-10)), and the rate of inactivation of PON1 was
determined by monitoring arylesterase activity, as outlined
under “Experimental Procedures” (Fig. 13, A and B). This
approach has previously been used to examine and characterize
human and rabbit PON activity stabilities (76, 77). A very slow
inactivation of WT rPON1 was observed in the presence of
rHDL (Fig. 13A), consistent with previous reports that HDL
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FIGURE 6. Experimental scheme using pac-PC to investigate pac-PCrPON1 interactions. rHDL incorporating the 2 mol % pac-PC was incubated
with His-tagged rPON1, and cross-linking was performed with brief exposure
to UV light (365 nm) and enriched by using Ni-NTA resin as described under
“Experimental Procedures.” Immobilized PON1-containing phospholipid
adducts were biotinylated via click chemistry and purified using neutravidin,
digested with trypsin, and processed as described in Fig. 2. Lipid adductedmodified rPON1 peptides were eluted from the beads and base-treated to
remove bulk lipid and allow facile identification of the modification sites on
rPON1 by LC/MS/MS and searching for glycerol-phosphate-modified peptides, which were detected by a static modification (⫹226.061) applied to
each amino acid residue. Details are described under “Experimental
Procedures.”
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FIGURE 7. Illustration of tandem mass spectra from rPON1 peptide Ile291–Lys-297 and its cross-linking product with pac-PC. The tandem mass
spectra shown are rPON1 peptide Ile-291–Lys-297 (A) and rPON1 peptide
Ile-291–Lys-297 (B), carrying a modification (⫹226.061) at Tyr-293. The pacPC-modified amino acid and related b, y ions are labeled with *.

particles stabilize PON1 activity (77). Addition of detergent
(0.1% tergitol, Nonidet P-10) to WT rPON1 showed an intermediate rate of inactivation, whereas rPON1 incubated with
buffer alone showed a relatively rapid decay in activity (Fig.
13A). In contrast, no protective effects were observed when the
pan-K rPON1 mutant was incubated with either rHDL or
detergent (0.1% tergitol, Nonidet P-10), suggesting PON1
Leu-9, Tyr-185, and Tyr-293 additionally contribute to the
HDL-dependent stabilization of PON1 activity to thermal
denaturation and detergents.
Because PON1 Tyr-293 is photo-labeled by pac-PC to a
greater extent (estimated 10 –20-fold) compared with the adjacent Tyr-294 residue, we decided to assess the functional significance of each residue to HDL binding/stabilization of PON1
activity. PON1 Tyr-293 and Tyr-294 were individually mutated
to Lys, and their PON1 activity (measured as arylesterase activity) was determined (Fig. 14A). PON1 Y293K and Y294K both
possess catalytic activity. Interestingly, the specific activity of
freshly isolated Y294K mutant appears modestly reduced compared with the WT and Y293K forms of the enzyme. To explore
the strength and functional impact of the HDL-PON1 interac-
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tion with each PON1 residue, we further examined the stability
of each mutant (Y293K versus Y294K) to inactivation in the
presence or absence of rHDL, because both our studies (Fig. 13)
and those of others (76, 77) show this is an excellent functional
readout of the PON1-HDL interaction. Incubation of all PON1
forms (either WT or both mutants) in buffer containing EDTA
and ␤-mercaptoethanol at 37 °C without HDL resulted in rapid
loss of activity (data not shown). However, in the presence of
HDL, the rate of PON1 inactivation in the WT versus mutant
PON1 forms was markedly different and followed the order
Y293K ⬎ Y294K ⬎⬎ WT (Fig. 14B). WT PON1 was completely
stabilized to inactivation by binding to HDL over the time
course examined. In contrast, Y293K was inactivated much
faster and was less stabilized by HDL than the Y294K mutant,
which showed intermediate deactivation rate (Fig. 14). These
results are consistent with the pac-PC labeling studies, which
suggest PON1 Tyr-293 plays a more significant role in PON1HDL binding than PON1 Tyr-294 (because the extent of
pac-PC labeling of Tyr-293 was 10 –20-fold greater than
Tyr-294).

Discussion
This study is significant for two distinct reasons. First, in
general terms, it describes the development and characterization of a novel photoactivatable, affinity-taggable (via click
chemistry), phospholipid probe (pac-PC) and the necessary
sample processing and mass spectrometry-based analytical
platform amenable for the facile discovery of specific residues
on proteins involved in docking to phospholipid surfaces.
Importantly, in addition to the inherent specificity and affinity
enrichment steps enabled by the probe design, the sample processing and analyses methodology developed enables existing
mass spectrometry software programs to be used for automated
VOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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FIGURE 8. Crystal structure of rPON1 with highlighted residues that
cross-linked with photoactivatable lipid probes. Shown is an image of
human PON1 crystal structure (Protein Data Bank code 3SRE), with residues
participating in the HDL-binding interface highlighted. Leu-9 (which is not
shown on the structure), Tyr-185, and Tyr-293 (yellow) were identified that
cross-linked with pac-PC. Tyr-294 (cyan) was later identified that also crosslinked with pac-PC but with much lower abundance (less than 5%) compared
with Tyr-293, using the selective ion monitoring mode. Tyr-71 (blue) was previously identified in cross-linking experiments. All of these residues are
located in the hypothetical HDL binding domain (above the dashed line,
according to PON1 crystal structure and hydropathy analyses).
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FIGURE 9. Significant differences in cross-linking formation between pacPC/Tyr-293 versus pac-PC/Tyr-294 demonstrate the spatial sensitivity
and specificity of using pac-PC to interrogate lipid-protein interactions
at the interface of PON1 and HDL. A, chromatogram of the selective ion
monitoring m/z 586.3 corresponding to rPON1 peptide Ile-291–Lys-297 carrying hydrolyzed pac-PC modification group (⫹226.061). A new peptide that
has the same m/z value but slightly different retention time was isolated as
the small shoulder peak (peak 1) on the chromatogram. B, new isolated tandem mass spectrum of rPON1 peptide Ile-291–Lys-297 carrying hydrolyzed
pac-PC modification group (⫹226.061) at Tyr-294.

peptide identification, a significant advance over existing lipid
photoactivatable probes. Second, on a more specific level, use of
the novel probe, pac-PC, when incorporated into rHDL for
proof of concept studies, helped to define three key residues on
PON1 involved in HDL docking and stabilization of PON1 catalytic activity (Leu-9, Tyr-185, and Tyr-293).
In prior studies, we sought to define precise residues on
PON1 that are involved in interaction with HDL cholesterol by
incorporating a synthetic photoactivatable cholesterol analogue containing a diazirine moiety at C6 of the sterol into nascent HDL (31). The diazirine group, because of its position and
hydrophilicity, is predicted to predominantly be exposed at the
surface of the HDL particle. Although one residue of PON1,
Tyr-71 (Fig. 8), was discovered in these early studies, the laborious mass spectrometry analyses required to detect a cholestanyl adduct within a sea of PON1 peptides was a major limitation of the approach. The absence of an affinity tag resulted in
extremely low abundance of photolabeled peptides (one in ten
thousand to million), making their identification tedious and
extremely difficult. The new tool developed herein has numerJANUARY 22, 2016 • VOLUME 291 • NUMBER 4

FIGURE 11. PON1 residues Leu-9, Tyr-185, and Tyr-293 are functionally
important for preservation of PON1 activity. A, paraoxonase activity; B,
arylesterase activity of purified rPON1 WT, pan-E, and pan-K mutants. Purified
rPON1 pan-K mutant demonstrated a specific activity of ⬃50% paraoxonase
activity and ⬃80% arylesterase activity compared with rPON1 WT, whereas
rPON1 pan-E mutant demonstrated almost complete loss of activity with
either substrate. Data shown represent the mean ⫾ S.D. of triplicate
determinations.

ous advantages. Importantly, it couples the specificity of a very
short lived diradical intermediate upon photoactivation with a
suitable affinity tag for enrichment (alkyne-azide-driven click
chemistry to biotinylate). During the preparation of this study,
a photoactivatable cholesterol probe with an affinity tag was
reported and applied to globally map cholesterol-protein
interactions in living cells (72). Instead, we designed a totally
different photoactivatable probe (an analogue of phosphatidylcholine) to investigate protein-membrane or lipoprotein interactions. We originally chose to synthesize and characterize
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FIGURE 10. Characterizations of site-specific rPON1 mutants. All mutants
were compared with the recombinant PON1 variant G3C9 (wild type like
activity, rPON1 WT). Residues (Leu-9, Tyr-185 and Tyr-293) were mutated to
either glutamic acid (rPON1 pan-E) or lysine (rPON1 pan-K). A, purified rPON1
WT, pan-E, and pan-K proteins were fractionated by 12% SDS-PAGE and
stained with Coomassie Blue. B, circular dichroism spectra of purified rPON1
WT, pan-E, and pan-K proteins. rPON1 forms (WT, pan-E, and pan-K mutants)
were analyzed at ambient temperature in continuous scan mode with a 1-nm
bandwidth (100,000 counts/step). Details are described under “Experimental
Procedures.”
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TABLE 2
The binding affinities between rPON1 mutants (WT, pan-E, and pan-K) and recombinant nascent HDL particles through surface plasmon
resonance
Recombinant nascent HDL was directly immobilized on a CM5 sensor chip. Samples of the indicated rPON1 ranging from 500 to 2000 nM were prepared in PON1 activity
buffers (50 mM Tris, 50 mM NaCl, 1 mM CaCl2, pH 8.0) and flowed over the surface of the sensor chip at a flow rate of 20 l/min. The association constant rate (kon),
dissociation constant rate (koff), and apparent dissociation constants (Kd) are listed in the table.
rPON1

Peptides with mutated amino acids

kon (1/ms)

koff (1/s)

Kd (1/M)

WT

2

AKLTALTLLGLGLALFDGQK21
291
IFYYDPK297
180
ATNDHYFADPY190

1.2 ⫻ 103

8.5 ⫻ 10⫺7

7.1 ⫻ 10⫺10

2

AKLTALTELGLGLALFDGQK21
IFEYDPK297
180
ATNDHEFADPY190

850

5.0 ⫻ 10⫺2

5.9 ⫻ 10⫺5

2

42

6.0 ⫻ 10⫺5

1.4 ⫻ 10⫺6

pan-E

291

pan-K

AKLTALTKLGLGLALFDGQK21
IFKYDPK297
180
ATNDHKFADPY190

291

this probe design due to the simplicity of its chemical structure
and the relatively similar van der Waals size of the diazirine ring
versus the trimethylamine of the choline headgroup moiety. We
also recognized that pac-PC is convenient to chemically synthesize, and early control studies indicated it was stable enough
under ambient light exposure to simplify its use. Later, during
the mass spectrometry analysis of cross-linked peptide adducts,
we found an unexpected advantage of this new probe that
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greatly enhances its potential utility, i.e. its ability to be used
with commercial platform peptide sequencing software. Specifically, although the initial mass spectra obtained of lipid-adducted peptides were not easily recognized by current data
analysis programs, addition of a base-hydrolysis step to remove
the bulky lipid side chains was found to simplify automated data
acquisition. Thus, using pac-PC under the methodology developed herein, mass spectra of glycerophosphate-tethered peptides are readily recognized by extant state of the art data analVOLUME 291 • NUMBER 4 • JANUARY 22, 2016
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FIGURE 12. PON1 residues Leu-9, Tyr-185, and Tyr-293 are functionally
important for HDL binding. Surface plasmon resonance sensorgrams of the
binding of various concentrations of rPON1 are shown. A, WT; B, pan-K mutant
to rHDL particles. rHDL was directly immobilized on a CM5 sensor chip. Samples of rPON1 ranging from 500 to 2000 nM were prepared in PON1 activity
buffers and flowed over the surface of the sensor chip as described under
“Experimental Procedures.” The apparent dissociation constants (Kd) were
obtained by fitting background-subtracted SPR binding data to the 1:1 binding with drifting baseline model within the BIAevaluation software version
4.0.

FIGURE 13. PON1 residues Leu-9, Tyr-185, and Tyr-293 are functionally
important to promote PON1 stabilization. Kinetics of the inactivation of
rPON1 WT (A) pan-K (B) in the solution of excess rHDL particles, 0.1% tergitol,
or buffer only are shown. Recombinant PON1 WT and pan-K were preincubated with rHDLs (excess), 0.1% tergitol (NP-10), or PON1 activity buffer. Inactivation was initiated by adding an equal volume of denaturing buffer and
incubating the samples as described under “Experimental Procedures.”
Aliquots were taken at the indicated time points, and arylesterase activities were examined. Data shown represent the mean ⫾ S.D. of triplicate
determinations.
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ysis programs (e.g. SEQUEST) by applying a static modification
of ⫹226.061 atomic mass units to each amino acid for peptide
analyses. This feature of the present methodology is unique,
and it markedly simplifies the identification process of affinitytagged peptides and the critical residue(s) involved in lipid
adduct formation.
Some potential limitations about pac-PC are worth noting.
The current probe design for pac-PC will likely preferentially
recognize a subset of residues on a docking protein, such as
those that are involved with the initial interaction at or near a
membrane surface or lipoprotein interface. Indeed, it is possible that the pac-PC design developed may not optimally interrogate regions of lipid-binding proteins that penetrate far into
the acyl chain region of membrane bilayers or lipoproteins.
Based upon the methodology developed herein, however, one
can reasonably envision future development of alternative
JANUARY 22, 2016 • VOLUME 291 • NUMBER 4
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FIGURE 14. PON1 adjacent residues Tyr-293 and Tyr-294 play different
roles in PON1 activity and stabilization of PON1 through HDL interaction. A, arylestrase activity of rPON1 WT, Y293K, and Y294K mutants in the
presence of rHDL are shown. B, kinetics of the inactivation of rPON1 WT,
Y293K, and Y294K mutants in the presence of excess HDL particles is shown.
rPON1WT, Y293K, and Y294K were preincubated with rHDLs as described
under “Experimental Procedures,” and inactivation was initiated by adding an
equal volume of denaturing buffer (containing metal chelator and reducing
agent) and incubating the samples at 37 °C as described under “Experimental
Procedures.” Aliquots were taken at the indicated time points, and arylesterase activity in reactions was determined. Data shown represent the
mean ⫾ S.D. of triplicate determinations.

pac-PC analogues where the diazirine group (or alternative
photoactivatable moiety) is placed at different positions along
one of the fatty acyl side chains to probe residues on docking
proteins that penetrate to greater depths of a hydrophobic
surface. Base hydrolysis of these would generate peptides
adducted to the fatty acyl moiety harboring the diazirine
group. Similarly, incorporation of the photo-affinity group
into phospholipids of alternative classes (headgroups), and
thus potential biological functionality, might further expand
the utility of these tools.
In our current application of probing the PON1-HDL interface, visual inspection of the location of the PON1 residues
identified (Leu-9, Tyr-185 and Tyr-293) shows they are all
localized in close vicinity to a hypothetical PON1 hydrophobic
binding surface based upon a recently reported PON1 crystal
structure and hydropathy analyses (Fig. 8) (73). Of note, residue
Leu-9 is close to the N terminus of rPON1, which was not visualized in the crystal structure. However, the N-terminal helix
(helix 1) of PON1 has previously been suggested to play an
important role in PON1-HDL interaction based upon deletion
mutant studies. Specifically, the recombinant PON1 truncated
variant (⌬20, lacking the first 20 amino acids) was reported to
have much lower binding affinity for HDL particles compared
with the full-length version (77). PON1 Tyr-185 is located on
the loop adjacent to helix 2, whereas Tyr-293 is at the end of
helix 3. However, they are all in relatively close spatial proximity
and together define an interfacial docking surface for PON1 on
HDL (Fig. 8). Prior studies have suggested helices 2 (Asp188Leu198) and 3 (Asn287-Tyr293) may potentially participate in
PON1-HDL interactions based on the analyses of the exposed
hydrophobic surfaces on the PON1 crystal structure (73), yet
no experimental validation nor specific residues in these
regions have been examined for their functional significance in
lipid binding. Interestingly, two hydrophobic residues (Tyr-190
and Trp-194) on helix 2, previously hypothesized to potentially
be involved in HDL anchoring based on their hydrophobicity
(73), were not identified to cross-link with the photo-lipid
probe in this study despite extensive searches for these adducts.
One possible explanation is that apoA-I of HDL may prevent
contact between these PON1 residues and the photoactivatable lipid probe within the surface of the HDL particle. By
using hydrogen-deuterium exchange mass spectrometry
analysis, we previously identified two regions on apoA-I of
nascent HDL that interact with PON1 (31), and these peptides are predicted to be in close spatial proximity (exactly
opposite to each other on the anti-parallel apoA-I chains of
nascent HDL) (78). Although speculative at present, it is
conceivable that these residues on PON1 helix 2 may directly
interact with the hydrophobic surface of one or both of these
two anti-parallel regions of apoA-I, thus reducing their
access to the phospholipid surface on HDL particles.
Another possibility is simply that neither of the two PON1
hydrophobic residues (Tyr-190 and Trp-194) on helix 2 play a
role in PON1-HDL interaction.
Our mutagenesis studies of PON1 Leu-9, Tyr-185, and Tyr293 confirm their functional significance for PON1-HDL interaction. The identified phospholipid adducts with residues Tyr185 and Tyr-293 are consistent with a role of at least portions of

Photoaffinity Probe to Define Protein, Phospholipid Contacts

1902 JOURNAL OF BIOLOGICAL CHEMISTRY

exerts its anti-oxidant and cardioprotective effects. Further
studies in this area seem warranted.
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helix 2 and 3 of PON1 functioning in the HDL interaction.
These studies thus provide structural information for how
these helix domains of PON1 are anchored to the HDL phospholipid surface (via PON1 Tyr-185 and Tyr-293). Interestingly, as shown in Fig. 8, the crystal structure of rPON1 (73)
reveals that the two adjacent tyrosine residues we examined in
detail (Tyr-293 and Tyr-294), although close, are positioned in
opposite orientations. Tyr-293, which was more readily identified as a covalent adduct to the photo-affinity phospholipid
probe (⬃20-fold greater), faces toward the hypothetical HDL
lipid surface where it can support PON1 binding to the lipid
HDL phase. In contrast, the crystal structure predicts Tyr-294
is oriented virtually 180° in the opposite direction away from
the potential HDL-binding interface. Thus, despite the theoretically equivalent reactivity of the phenol moiety of each residue
with a carbene diradical, and their close spatial proximity (the
␣-carbons of each Tyr are within 4.8 Å in the crystal structure
(73)), significant differences in the ease of covalent adduct formation was noted between these residues. The markedly different orientation of the tyrosine residues likely explains this difference. This interesting finding also demonstrates the spatial
sensitivity and specificity of our approach to interrogate lipidprotein interactions. It is also notable that our mutagenesis
studies verified that the Y293K mutant was less stable to denaturation in the presence of HDL compared with either Y294K
or WT PON1.
PON1 is an HDL-associated protein with cardioprotective
functions (36, 37). Its antioxidant and anti-inflammatory effects
have been extensively observed in vitro and in vivo (12, 31, 32,
36, 37, 79). Some pharmaceutical effort has even been aimed at
developing PON1, or PON1-HDL complexes, as an injectable
biological agent for various indications ranging from the treatment of exposure to organophosphate nerve agents to the prevention or treatment of cardiovascular diseases (80, 81). Progress in this arena has been hampered by poor stability of the
injected PON1 into the systemic circulation, and it has been
suggested that an improved understanding of specific structural features critical to PON1 docking to the HDL particle and
that are functionally important for maintenance of PON1 stability and catalytic activity may assist in these endeavors (82,
83). This study may thus help with future therapeutic agent
efforts using PON1.
Finally, our recent finding that PON1, myeloperoxidase,
and HDL form a functional ternary complex in vivo (31)
provides a unique perspective for the understanding of the
cardioprotective functions of PON1. Myeloperoxidase is a
leukocyte-derived heme protein that often initiates lipid peroxidation and protein oxidative damage during inflammation (43, 48, 84 – 87). The fact that PON1 binds to both
myeloperoxidase and HDL on the HDL surface, partially
inhibiting myeloperoxidase activity, was shown to also help
PON1 inhibit initiation of lipid peroxidation by myeloperoxidase. Alternative studies have suggested the lactonase
activity of PON1 contributes to its anti-oxidant activity
through hydrolysis of specific lipid peroxidation products
(88, 89). A better understanding of the critical residues supporting PON1 interactions with HDL may thus help better
understand the mechanisms through which the protein
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